by Dr. Ed Weber | Mar 10, 2022 | PCa Commentary, Uncategorized
Heterogeneity is the Achilles heel of prostate cancer staging. Intermediate-risk cancers with Gleason Score 3+4 and 4+3 (i.e., Grade Groups 2 and 3) are especially fraught with this complexity. A report, “Molecular Analysis of Low-Grade Prostate Cancer Using...
by Dr. Ed Weber | Feb 3, 2022 | PCa Commentary, Uncategorized
[A prior Commentary, Vol. 138, September 2019 https://www.prostatecancerfree.org/pca-commentary-138-active-surveillance-update-and-new-developments/ covered this topic and remains current. This Commentary will build upon it.] Guidelines suggesting ‘best practice’...
by Dr. Ed Weber | Apr 6, 2018 | PCa Commentary, Uncategorized
A test for the splice-variant AR-V7, Oncotype Dx AR-V7 Nucleus Detect (Genomic Health, Inc.), has become commercially available. This Commentary will focus on the clinical significance of test results — their predictive and prognostic value. The Major Foundation...
